Researchers concluded that empagliflozin offers a promising dual benefit for glucose control and weight reduction, with ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate ...

The drug industry is facing one of the largest patent cliffs in recent history. Will that mean dealmaking at the annual J.P.

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the drug. Adding CKD to the ...

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

Jardiance is the market leader in the SGLT2 ... but it became the first SGLT2 drug to be approved for CKD in diabetics last October, based on the results of the CREDENCE trial.

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. And retail traders should know. We ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Empagliflozin 25 and 10 mg ... We did not compare safety data. The usual first drug for type 2 diabetes is metformin, with sulfonylurea in those who cannot tolerate metformin. NICE is appraising the ...